tradingkey.logo

Anika Therapeutics Inc

ANIK
查看详细走势图
9.570USD
0.000
交易中 美东报价延迟15分钟
138.01M总市值
亏损市盈率 TTM

Anika Therapeutics Inc

9.570
0.000
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

0.00%

5天

+0.10%

1月

-3.14%

6月

-9.63%

今年开始到现在

-41.86%

1年

-41.32%

查看详细走势图

TradingKey Anika Therapeutics Inc股票评分

单位: USD 更新时间: 2025-12-19

操作建议

Anika Therapeutics Inc当前公司基本面数据相对非常健康,增长潜力稳定。当前估值合理,在医疗设备与耗材行业排名48/208位。机构持股占比非常高,近一月多位分析师给出公司评级为强力买入。最高目标价16.00。中期看,股价处于平稳状态。近一个月,市场表现一般,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Anika Therapeutics Inc评分

相关信息

行业排名
48 / 208
全市场排名
131 / 4582
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 2 位分析师
强力买入
评级
16.000
目标均价
+66.15%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Anika Therapeutics Inc亮点

亮点风险
Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
利润高增长
公司净利润处于行业前列,最新年度总收入119.91M美元
估值合理
公司最新PE估值-4.21,处于3年历史合理位
机构减仓
最新机构持股12.37M股,环比减少0.01%
先锋集团持仓
明星投资者先锋集团持仓,最新持仓市值780.66K

Anika Therapeutics Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Anika Therapeutics Inc简介

Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
公司代码ANIK
公司Anika Therapeutics Inc
CEOBlanchard (Cheryl Renee)
网址https://anika.com/

常见问题

Anika Therapeutics Inc(ANIK)的当前股价是多少?

Anika Therapeutics Inc(ANIK)的当前股价是 9.570。

Anika Therapeutics Inc的股票代码是什么?

Anika Therapeutics Inc的股票代码是ANIK。

Anika Therapeutics Inc股票的52周最高点是多少?

Anika Therapeutics Inc股票的52周最高点是18.370。

Anika Therapeutics Inc股票的52周最低点是多少?

Anika Therapeutics Inc股票的52周最低点是7.870。

Anika Therapeutics Inc的市值是多少?

Anika Therapeutics Inc的市值是138.01M。

Anika Therapeutics Inc的净利润是多少?

Anika Therapeutics Inc的净利润为-56.38M。

现在Anika Therapeutics Inc(ANIK)的股票是买入、持有还是卖出?

根据分析师评级,Anika Therapeutics Inc(ANIK)的总体评级为--,目标价格为16.000。

Anika Therapeutics Inc(ANIK)股票的每股收益(EPS TTM)是多少

Anika Therapeutics Inc(ANIK)股票的每股收益(EPS TTM)是-2.271。
KeyAI